Acute Promyelocytic Leukemia as a Model for Cross-Talk Between Interferon and Retinoic Acid Pathways: From Molecular Biology to Clinical Applications

References

• Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Gallon D. A. G., Gralnick H. R., Sultan C. Proposal for the classification of the acute leukemias. Br. J. Haematol. 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Groopman J., Ellman L. Acute promyelocytic leukemia. Am. J. Hematol. 1979; 7: 395–408
   PubMed Web of Science ®Google Scholar
• Stone R. M., Mayer R. J. The unique aspects of acute promyelocytic leukaemia. J. Clin. Oncol. 1990; 8: 1913–1910
   PubMed Web of Science ®Google Scholar
• Borrow J., Goddard A. D., Sheer D., Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990; 249: 1577–1580
   PubMed Web of Science ®Google Scholar
• De ThÉ H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990; 347: 558–561
   PubMed Web of Science ®Google Scholar
• Longo L., Pandolfi P. P., Biondi A., Rambaldi A., Mencarelli A., Lo Coco F., Diverio D., Pegoraro L., Avanzi G., Tabilio A., Zangrilli D., Alcalay M., Donti E., Grignani F., Pelicci P. G. Rearrangements and aberrant expression of the RARa gene in acute promyelocytic leukemias. J. Exp. Med. 1990; 172: 1571–1575
   PubMed Web of Science ®Google Scholar
• Alcalay M., Zangrilli D., Pandolfi P. P., Longo L., Mencarelli A., Giacomucci A., Rocchi M., Biondi A., Rambaldi A., Lo Coco F., Diverio D., Donti E., Grignani F., Pelicci P. G. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc. Natl. Acad. Sci. USA 1991; 172: 1977–1981
   Web of Science ®Google Scholar
• Pandolfi P. P., Grignani F., Alcalay M., Mencarelli A., Biondi A., Lo Coco F., Pelicci P. G. Structure and origin of the acute promyelocytic leukemia myl/RARα cDNA and characterization of its retinoid-binding and trans-activation properties. Oncogene 1991; 6: 1285–1292
   PubMed Web of Science ®Google Scholar
• De ThÉ H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. The PML/RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukaemia encodes a functionally altered RAR. Cell 1991; 66: 675–684
   PubMed Web of Science ®Google Scholar
• Kakizuka A., Miller W. H., Jr., Umesono K., Warrell R. P., Jr., Frankel S. R., Murty V. V. V. S., Dmitrovsky E., Evans R. M. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 1991; 66: 663–674
   PubMed Web of Science ®Google Scholar
• Grignani F., Fagioli M., Alcalay M., Longo L., Pandolfi P. P., Donti E., Biondi A., Lo Coco F., Pelicci P. G. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994; 83: 10–25
   PubMed Web of Science ®Google Scholar
• Huang M. E., Yu-Chen Y., Shu-Rong C., Chai J., Lin Z., Long J., Wang Z. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–560
   PubMed Web of Science ®Google Scholar
• Degos L., Chomienne C., Daniel M. T., Berger R., Dombret H., Fenaux P., Castaigne S. Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid. Lancet 1990; 336: 1440–1441
   PubMed Web of Science ®Google Scholar
• Warrell R. P., Jr., De ThÉ H., Wang Z. Y., Degos L. Acute promyelocytic leukemia. N. Engl. J. Med. 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Mangelsdorf D. J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., et al. The nuclear receptor super-family: the second decade. Cell 1995; 83: 835–9
   PubMed Web of Science ®Google Scholar
• Wang Z. G., Delva L., Gaboli M., Zhang H., Rivi R., Cordon-Cardo C., Grosveld F., Pandolfi P. P. Targeted disruption of the PML gene results in tumor susceptibility. 1997, Submitted).
   Google Scholar
• Pandolfi P. P., Alcalay M., Fagioli M., Zangrilli D., Mencarelli A., Diverio D., Biondi A., Lo Coco F., Rambaldi A., Grignani F., Rochette-Egly C., Gaub M.-P., Chambon P., Pelicci P. G. Genomic variability and alternative splicings generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukemias. EMBO J. 1992; 11: 1397–1407
   PubMed Web of Science ®Google Scholar
• Stadler M., Chelbi-Alix M. K., Koken M. H., Venturini L., Lee C., Saib A., Quignon F., Pelicano L., Guillemin M. C., Schindler C., et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 1995; 11: 2565–73
   PubMed Web of Science ®Google Scholar
• Lavau C., Marchio A., Fagioli M., Jansen J., Falini B., Lebon P., Grosveld F., Pandolfi P. P., Pelicci P. G., Dejean A. The PML gene is a primary target for interferon. Oncogene 1995; 11: 871–876
   PubMed Web of Science ®Google Scholar
• Chelbi-Alix M. K., Pelicano L., Quignon F., Koken M. H., Venturini L., Stadler M., Pavlovic J., Degos L., De ThÉ H. Induction of the PML protein by interferons in normal and APL cells. Leukemia 1995; 9: 2027–33
   PubMed Web of Science ®Google Scholar
• Nason-Burchenal K., Gandini D., Botto M., Allopenna J., Seale J. R. C., Cross N. C. P., Goldman J. M., Dmitrovsky E., Pandolfi P. P. Interferon augments PML and PML/RARa expression in normal myeloid and acute promyelocytic cells and cooperates with all-trans-retinoic acid to induce maturation of a retinoid resistant promyelocytic cell line. Blood 1996; 889: 3926–3936
   Google Scholar
• Kumar R., Korutla L. Growth inhibition of human acute promyelocytic leukemia NB-4 cells by interferons and all-trans retinoic acid: trans-modulation of inducible gene expression pathways. Anticancer Res. 1995; 15: 353–60
   PubMed Web of Science ®Google Scholar
• Matikainen S., Ronni T., Lehtonen A., Sareneva T., Melen K., Nordling S., Levy D. E., Julkunen I. Retinoic acid induces signal transducer and activator of transcription (STAT) 1, STAT2, and p48 expression in myeloid leukemia cells and enhances their responsiveness to interferons. Cell. Growth Differ. 1997; 8: 687–98
   PubMedGoogle Scholar
• Trinchieri G., Rosen M., Perussia B. Retinoic acid cooperates with tumor necrosis factor and immune interferon in inducing differentiation and growth inhibition of the human promyelocytic leukemic cell line HL-60. Blood 1987; 69: 1218–24
   PubMed Web of Science ®Google Scholar
• Hemmi H., Breitman T. R. Combinations of recombinant human interferons and retinoic acid synergistically induce differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1987; 69: 501–7
   PubMed Web of Science ®Google Scholar
• Ho C. K. Synergistic anticellular effect of a combination of beta-interferon and retinoic acid against U937 cells. Cancer Res. 1985; 45: 5348–51
   PubMed Web of Science ®Google Scholar
• Kohlhepp E. A., Condon M. E., Hamburger A. W. Recombinant human interferon alpha enhancement of retinoic-acid-induced differentiation of HL-60 cells. Exp. Hematol 1987; 15: 414–8
   PubMed Web of Science ®Google Scholar
• Matikainen S., Ronni T., Hurme M., Pine R., Julkunen I. Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood 1996; 88: 114–23
   PubMed Web of Science ®Google Scholar
• Gianni M., Terao M., Fortino I., Licalzi M., Viggiano V., Barbui T., Rambaldi A., Garattini E. Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 1997; 89: 1001–12
   PubMed Web of Science ®Google Scholar
• Liu M., Iavarone A., Freedman L. P. Transcriptional activation of the human p21 (WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J. Biol. Chem. 1996; 271: 31723–8
   PubMed Web of Science ®Google Scholar
• Chin Y. E., Kitagawa M., Su W. C., You Z. H., Iwamoto Y., Fu X. Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996; 272: 719–22
   PubMed Web of Science ®Google Scholar
• Landolfo S., Gribaudo G., Angeretti A., Gariglio M. Mechanisms of viral inhibition by interferons. Pharmacol. Ther. 1995; 65: 415–42
   PubMed Web of Science ®Google Scholar
• David M. Transcription factors in interferon signaling. Pharmacol. Ther. 1995; 65: 149–61
   PubMed Web of Science ®Google Scholar
• Staeheli P. Interferon-induced proteins and the antiviral state. Adv. Virus Res. 1990; 38: 147–200
   PubMedGoogle Scholar
• Lengyel P. Tumor-suppressor genes: news about the interferon connection. Proc. Natl. Acad. Sci. USA 1993; 90: 5893–5
   PubMed Web of Science ®Google Scholar
• Gutterman J. U. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. 1994; 91: 1198–205, USA
   PubMed Web of Science ®Google Scholar
• Sen G. C., Lengyel P. The interferon system. A bird's eye view of its biochemistry. J. Biol. Chem. 1992; 267: 5017–20
   PubMed Web of Science ®Google Scholar
• Darnell J. E., Jr., Kerr I. M., Stark G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415–21
   PubMed Web of Science ®Google Scholar
• Schindler C., Darnell J. E., Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 1995; 64: 621–51
   PubMed Web of Science ®Google Scholar
• Ihle J. N. STATs: signal transducers and activators of transcription. Cell 1996; 84: 331–4
   PubMed Web of Science ®Google Scholar
• Dile J. N., Witthuhn B. A., Quelle F. W., Yamamoto K., Thierfelder W. E., Kreider B., Silvennoinen O. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem. Sci. 1994; 19: 222–7
   PubMed Web of Science ®Google Scholar
• Ziemiecki A., Harpur A. G., Wilks A. F. JAK protein tyrosine kinase: their role in cytokine signalling. Trends in Cell Biol. 1994; 4: 207–212
   PubMedGoogle Scholar
• Lew D. J., Decker T., Strehlow I., Darnell J. E. Overlapping elements in the guanylate-binding protein gene promoter mediate transcríptional induction by alpha and gamma interferons. Mol. Cell. Biol 1991; 11: 182–91
   PubMed Web of Science ®Google Scholar
• Chambon P. The retinoid signaling pathway: molecular and genetic analyses. Semin. Cell Biol. 1994; 5: 115–25
   PubMedGoogle Scholar
• Mangelsdorf D. J., Evans R. M. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841–50
   PubMed Web of Science ®Google Scholar
• Leid M., Kastner P., Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem. Sci. 1992; 17: 427–33
   PubMed Web of Science ®Google Scholar
• Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 1996; 10: 940–54
   PubMed Web of Science ®Google Scholar
• Glass C. K., Rose D. W., Rosenfeld M. G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 1997; 9: 222–32
   PubMed Web of Science ®Google Scholar
• De ThÉ H., Marchio A., Tiollais P., Dejean A. Differential expression and ligand regulation of the retinoic acid receptor α and β genes. EMBO J 1989; 8: 429–433
   PubMed Web of Science ®Google Scholar
• Collins S. J., Robertson K., Mueller L. Retinoic acid induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-α). Mol. Cell. Biol. 1990; 10: 2154–2163
   PubMed Web of Science ®Google Scholar
• Chomienne C., Balitrand N., Ballerini P., Castaigne S., De ThÉ H., Degos L. All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. J. Clin. Invest. 1991; 88: 2150–4
   PubMed Web of Science ®Google Scholar
• Robertson K. A., Emami B., Mueller L., Collins S. J. Multiple members of the retinoic acid receptor family are capable of mediating the granulocytic differentiation of HL-60 cells. Mol. Cell. Biol. 1992; 12: 3743–3749
   PubMed Web of Science ®Google Scholar
• Tsai S., Bartelmez S., Heyman R., Damm K., Evans R. M., Collins S. J. A mutated retinoic acid receptor-α exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. Genes Dev. 1992; 6: 2258–2269
   PubMed Web of Science ®Google Scholar
• Vasios G. W., Gold J. D., Petkovich M., Chambon P., Gudas L. J. A retinoic acid-responsive element is present in the 5′ flanking region of the laminin B1 gene. Proc. Natl. Acad. Sci. USA 1989; 86: 9099–103
   PubMed Web of Science ®Google Scholar
• Smith M. A., Parkinson D. R., Cheson B. D., Friedman M. A. Retinoids in cancer therapy. J. Clin. Oncol 1992; 10: 839–864
   PubMed Web of Science ®Google Scholar
• Gudas L. J. Retinoids and vertebrate development. J. Biol. Chem. 1994; 269: 15399–402
   PubMed Web of Science ®Google Scholar
• FroeschlÉ A., Camac G., Alric S., Montarras D., Pinset C., Rochette-Egly C., Bonnieu A. RXR alpha is essential for mediating the all-trans retinoic acid-induced growth arrest of C2 myogenic cells. Oncogene 1996; 12: 411–21
   PubMed Web of Science ®Google Scholar
• Pomponi F., Cariati R., Zancai P., De Paoli P., Rizzo S., Tedeschi R. M., Pivetta B., De Vita S., Boiocchi M., Dolcetti R. Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood 1996; 88: 3147–59
   PubMed Web of Science ®Google Scholar
• Ahn M. J., Nason-Burchenal K., Moasser M., Dmitrovsky E. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RARα or PML. Oncogene 1995; 10: 2307–2300
   PubMed Web of Science ®Google Scholar
• Schule R., Rangarajan P., Yang N., Kliewer S., Ransone L. J., Bolado J., Verma I. M., Evans R. M. Retinoic acid is a negative regulator of AP-1-responsive genes. Proc. Natl. Acad. Sci. USA 1991; 88: 6092–6
   PubMed Web of Science ®Google Scholar
• Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S. C., Heyman R. A., Rose D. W., Glass C. K., Rosenfeld M. G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85: 403–14
   PubMed Web of Science ®Google Scholar
• Lippman S. M., Glisson B. S., Kavanagh J. J., Lotan R., Hong W. K., Paredes-Espinoza M., Hittelman W. N., Holdener E. E., Krakoff I. H. Retinoic acid and interferon combination studies in human cancer. Eur. J. Cancer. 1993; 29A, Suppl 5, S9–13.
   Web of Science ®Google Scholar
• Moore D. M., Kalvakolanu D. V., Lippman S. M., Kavanagh J. J., Hong W. K., Borden E. C., Paredes-Espinoza M., Krakoff I. H. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin. Hematol. 1994; 31: 31–7
   PubMed Web of Science ®Google Scholar
• Lippman S. M., Lotan R., Schleuniger U. Retinoid-interferon therapy of solid tumors. Int. J. Cancer 1997; 70: 481–3
   PubMed Web of Science ®Google Scholar
• Lancillotti F., Giandomenico V., Affabris E., Fiorucci G., Romeo G., Rossi G. B. Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res. 1995; 55: 3158–64
   PubMed Web of Science ®Google Scholar
• Giandomenico V., Lancillotti F., Fiorucci G., Percario Z. A., Rivabene R., Malorni W., Affabris E., Romeo G. Retinoic acid and IFN inhibition of cell proliferation is associated with apoptosis in squamous carcinoma cell lines: role of IRF-1 and TGase II-dependent pathways. Cell Growth Differ. 1997; 8: 91–100
   PubMedGoogle Scholar
• Weihua X., Kolla V., Kalvakolanu D. V. Modulation of interferon action by retinoids. Induction of murine STAT1 gene expression by retinoic acid. J. Biol. Chem. 1997; 272: 9742–8
   PubMed Web of Science ®Google Scholar
• Kolla V., Lindner D. J., Xiao W., Borden E. C., Kalvakolanu D. V. Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J. Biol. Chem. 1996; 271: 10508–14
   PubMed Web of Science ®Google Scholar
• Harada H., Fujita T., Miyamoto M., Kimura Y., Maruyama M., Furia A., Miyata T., Taniguchi T. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989; 58: 729–39
   PubMed Web of Science ®Google Scholar
• Matsuyama T., Kimura T., Kitagawa M., Pfeffer K., Kawakami T., Watanabe N., Kundig T. M., Amakawa R., Kishihara K., Wakeham A., et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 1993; 75: 83–97
   PubMed Web of Science ®Google Scholar
• Tanaka N., Ishihara M., Kitagawa M., Harada H., Kimura T., Matsuyama T., Lamphier M. S., Aizawa S., Mak T. W., Taniguchi T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829–39
   PubMed Web of Science ®Google Scholar
• Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–4
   PubMed Web of Science ®Google Scholar
• Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interaeting proteinCip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805–16
   PubMed Web of Science ®Google Scholar
• Gu Y., Turck C. W., Morgan D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993; 366: 707–10
   PubMed Web of Science ®Google Scholar
• El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinder K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–25
   PubMed Web of Science ®Google Scholar
• Kano A., Watanabe Y., Takeda N., Aizawa S., Akaike T. Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. J. Biochem. (Tokyo) 1997; 121: 677–83
   PubMed Web of Science ®Google Scholar
• Hobeika A. C., Subramaniam P. S., Johnson H. M. IFNalpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 1997; 14: 1165–70
   PubMed Web of Science ®Google Scholar
• Sangfelt O., Erickson S., Einhorn S., Grander D. Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines. Oncogene 1997; 14: 415–23
   PubMed Web of Science ®Google Scholar
• Subramaniam P. S., Johnson H. M. A role for the cyclin-dependent kinase inhibitor p21 in the Gl cell cycle arrest mediated by the type I interferons. J. Interferon Cytokine Res. 1997; 17: 11–5
   PubMed Web of Science ®Google Scholar
• Biggs J. R., Kudlow J. E., Kraft A. S. The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J. Biol. Chem. 1996; 271: 901–6
   PubMed Web of Science ®Google Scholar
• Jiang H., Lin J., Su Z. Z., Collart F. R., Huberman E., Fisher P. B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9: 3397–406
   PubMed Web of Science ®Google Scholar
• Steinman R. A., Hoffman B., Iro A., Guillouf C., Liebermann D. A., El-Houseini M. E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 1994; 9: 3389–96
   PubMed Web of Science ®Google Scholar
• Scale J. R. C., Varma S., Swirsky D., Pandolfi P. P., Goldman J. M., Cross N. C. P. Quantification of PML-RARα transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia specific mRNA by alpha interferon. Br. J. Haematol. 1996; 95: 95–101
   PubMed Web of Science ®Google Scholar
• Peruzzi D., Deblasio T., Warrell R. P. J., Pandolfi P. P. Highly sensitive RT-PCR assay for detection of minimal residual disease in acute promyelocytic leukemia. Blood 1996; 88: 366a
   PubMedGoogle Scholar
• Bouteille M., Laval M., Dupuy-Coin A. M. In The Cell Nucleus, H. Busch. Academic Press, New York 1974; 5–64
   Google Scholar
• Ascoli C., Maul G. J. Identification of a novel nuclear domain. J. Cell. Biol. 1991; 112: 785–795
   PubMed Web of Science ®Google Scholar
• Koken M. H. M., Puvion-Dutilleui F., Guillemin M. C., Viron A., Linares-Cruz G., Stuurman N., De Jong L., Szostecki C., Calvo F., Chomienne C., Degos L., Puvion E., De ThÉ H. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J. 1994; 13: 1073–1083
   PubMed Web of Science ®Google Scholar
• Dyck J., Maul G. G., Miller W. H., Jr., Chen J. D., Kakizuka A., Evans R. M. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell 1994; 76: 333–343
   PubMed Web of Science ®Google Scholar
• Weis K., Rambaud S., Lavau C., Jansen J., Carvalho T., Carmo-Fonseca M., Lamond A., Dejean A. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 1994; 76: 345–56
   PubMed Web of Science ®Google Scholar
• Kastner P., Perez A., Lutz Y., Rochette-Egly C., Gaub M. P., Durand B., Lanotte M., Berger R., Chambon P. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J 1992; 11: 629–642
   PubMed Web of Science ®Google Scholar
• Raelson J. V., Nervi C., Rosenauer A., Benedetti L., Monczak Y., Pearson M., Pelicci P. G., Miller W. H., Jr. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996; 88: 2826–32
   PubMed Web of Science ®Google Scholar
• Yoshida H., Kitamura K., Tanaka K., Omura S., Miyazaki T., Hachiya T., Ohno R., Naoe T. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 1996; 56: 2945–8
   PubMed Web of Science ®Google Scholar
• Lanotte M., Martin-Thouvenin V., Najman S., Ballerini P., Valensi F., Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080–1086
   PubMed Web of Science ®Google Scholar
• Gianni M., Zanotta S., Terao M., Rambaldi A., Garattini E. Interferons induce normal and aberrant retinoic-acid receptors type alpha in acute promyelocytic leukemia cells: potentiation of the induction of retinoid-dependent differentiation markers. Int. J. Cancer 1996; 68: 75–83
   PubMed Web of Science ®Google Scholar
• Fenaux P., Chomienne C., Degos L. Acute promyelocytic leukemia: biology and treatment. Semin. Oncol 1997; 24: 92–102
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Regazzi M. B., Corso A. Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia. Leuk. Lymphoma 1996; 23: 539–43
   PubMed Web of Science ®Google Scholar
• Duprez E., Ruchaud S., Houge G., Martin-Thouvenin V., Valensi F., Kastner P., Berger R., Lanotte M. A retinoid acid ‘resistant’ t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia 1992; 6: 1281–7
   PubMed Web of Science ®Google Scholar
• Dermime S., Grignani F., Clerici M., Nervi C., Sozzi G., Talamo G. P., Marchesi E., Formelli F., Parmiani G., Pelicci P. G., et al. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pm1/RAR alpha protein. Blood 1993; 82: 1573–7
   PubMed Web of Science ®Google Scholar
• Rosenauer A., Raelson J. V., Nervi C., Eydoux P., Deblasio A., Miller W. H., Jr. Alterations in expression, binding to ligand and DNA, and transcriptional activity of rearranged and wild-type retinoid receptors in retinoid-resistant acute promyelocytic leukemia cell lines. Blood 1996; 88: 2671–82
   PubMed Web of Science ®Google Scholar
• Kizaki M., Matsushita H., Takayama N., Muto A., Ueno H., Awaya N., Kawai Y., Asou H., Kamada N., Ikeda Y. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood 1996; 88: 1824–33
   PubMed Web of Science ®Google Scholar
• Shao W., Benedetti L., Lamph W. W., Nervi C., Miller W. H., Jr. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 1997; 89: 4282–9
   PubMed Web of Science ®Google Scholar
• Koller E., Krieger O., Kasparu H., Lutz D. Restoration of all-trans retinoic acid sensitivity by interferon in acute promyelocytic leukaemia [letter] [see comments]. Lancet 1991; 338: 1154–5
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Corso A., Regazzi M. B., Iacona I., Bemasconi C. Modulation of all-trans retinoid acid pharmacokinetics in acute promyelocytic leukaemia by prolonged interferon-alpha therapy. Br. J. Haematol. 1995; 90: 928–30
   PubMed Web of Science ®Google Scholar
• Mu Z.-M., Chin K.-V., Liu J.-H., Lozano G., Chang K.-S. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell. Biol. 1994; 14: 6858–6867
   PubMed Web of Science ®Google Scholar
• Koken M. H. M., Linares-Cruz G., Quignon F., Viron A., Chelbi-Alix M. K., Sobczak-Thepot J., Juhlin L., Degos L., Calvo F., De ThÉ H. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995; 10: 1315–1324
   PubMed Web of Science ®Google Scholar
• Zheng A., Savolainen E. R., Koistinen P. All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia. Leuk. Res. 1996; 20: 243–8
   PubMed Web of Science ®Google Scholar
• Ferrero D., Carlesso N., Bresso P., Roux V., Pregno P., Gallo E., Pileri A. Suppression of in vitro maintenance of non-promyelocytic myeloid leukemia clonogenic cells by all-trans retinoic acid: modulating effects of dihy-droxylated vitamin D3, alpha interferon and 'stem cell factor'. Leuk. Res. 1997; 21: 51–8
   PubMed Web of Science ®Google Scholar
• Mahon F. X., Chahine H., Barbot C., Pigeonnier V., Jazwiec B., Reiffers J., Ripoche J. All-trans retinoic acid potentiates the inhibitory effects of interferon alpha on chronic myeloid leukemia progenitors in vitro. Leukemia 1997; 11: 667–73
   PubMed Web of Science ®Google Scholar
• Wadler S., Schwartz E. L., Haynes H., Rameau R., Quish A., Mandeli J., Gallagher R., Hallam S., Fields A., Goldberg G., McGill F., Jennings S., Wallach R. C., Runowicz C. D. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group. Cancer 1997; 79: 1574–80
   PubMed Web of Science ®Google Scholar
• Bonnefoix T., Gressin R., Jacrot M., Perron P., Swiercz P., Chaffanjon P., Sotto J. J. Growth modulation of freshly isolated non-Hodgkin's B-lymphoma cells induced by various cytokines and all-trans-retinoic-acid. Leuk. Lymphoma 1997; 25: 169–78
   PubMed Web of Science ®Google Scholar
• Massad L. S., Turyk M. E., Bitterman P., Wilbanks G. D. Interferon-alpha and all-trans-retinoic acid reversibly inhibit the in vitro proliferation of cell lines derived from cervical cancers. Gynecol. Oncol. 1996; 60: 428–34
   PubMed Web of Science ®Google Scholar
• Widschwendter M., Daxenbichler G., Culig Z., Michel S., Zeimet A. G., Mortl M. G., Widschwendter A., Marth C. Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines. Int. J. Cancer 1997; 71: 497–504
   PubMed Web of Science ®Google Scholar
• Avvisati G., Lo Coco F., Diverio D., Falda M., Ferrara F., Lazzarino M., Russo D., Petti M. C., Mandelli F. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–8
   PubMed Web of Science ®Google Scholar
• He L. Z., Tribioli C., Rivi R., Peruzzi D., Pelicci P. G., Soares V., Cattoretti G., Pandolfi P. P. Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc. Natl. Acad. Sci. USA 1997; 94: 5302–5307
   PubMed Web of Science ®Google Scholar
• Brown D., Kogan S., Lagasse E., Weissman I., Alcalay M., Pelicci P. G., Atwater S., Bishop J. M. A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 1997; 94: 2551–2556
   PubMed Web of Science ®Google Scholar
• Grisolano J. L., Wesselschmidt R. L., Pelicci P. G., Ley T. J. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences. Blood 1997; 89: 376–387
   PubMed Web of Science ®Google Scholar
• Licht J. D., Chomienne C., Goy A., Chen A., Scott A., Head D. R., Michaux J. L., Wu Y., Deblasio A., Miller W. H., Jr., Zelenetz A. D., Willman C. L., Chen Z., Chen S.-J., Zelent A., Macintyre E., Veil A., Cortes J., Kantarjian H., Waxman S. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 1995; 85: 1083–1094
   PubMed Web of Science ®Google Scholar
• Zelent A. Translocation of the RARa locus to the PML or PLZF gene in acute promyelocytic leukaemia. Br. J. Haematol. 1994; 86: 451–450
   PubMed Web of Science ®Google Scholar
• Pandolfi P. P. PML, PLZF and NPM in the pathogenesis of Acute Promyelocytic Leukemia. Haematologica 1996; 81: 472–482
   PubMedGoogle Scholar